Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
| Revenue (Most Recent Fiscal Year) | $411.33M |
| Net Income (Most Recent Fiscal Year) | $271.17M |
| PE Ratio (Current Year Earnings Estimate) | 9.17 |
| PE Ratio (Trailing 12 Months) | 5.20 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.46 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.24 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 4.19 |
| Pre-Tax Margin (Trailing 12 Months) | 95.32% |
| Net Margin (Trailing 12 Months) | 81.19% |
| Return on Equity (Trailing 12 Months) | 28.03% |
| Return on Assets (Trailing 12 Months) | 20.19% |
| Current Ratio (Most Recent Fiscal Quarter) | 16.01 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.18 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.21 |
| Inventory Turnover (Trailing 12 Months) | 3.15 |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.59 |
| Earnings per Share (Most Recent Fiscal Year) | $3.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $4.10 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 72.25M |
| Free Float | 70.79M |
| Market Capitalization | $1.52B |
| Average Volume (Last 20 Days) | 0.68M |
| Beta (Past 60 Months) | 0.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.01% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |